Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars
Calgary, Alberta--(Newsfile Corp. - 17 septembre 2026) - Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd'hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d'unités de la Société (les « Unités »)
2026-09-17 5:05 PM EDT | Marvel Biosciences Corp.
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
New York and Rockville, Maryland--(Newsfile Corp. - September 17, 2026) - OS
2026-09-17 6:00 AM EDT | OS Therapies
Cashu Research Initiates Coverage on K2 Gold Corporation (KTO)
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2026) - Cashu Research today initiated coverage on K2 Gold Corporation (TSXV: KTO) (OTCQX: KTGDF), focused on the company's 100%-owned Mojave Project in Inyo County, California. Read the full report: https://research.cashugroup.com/research-repo
Biotechnologies, Mines et métaux, Métaux précieux, Pétrole et gaz
2026-09-16 9:49 AM EDT | Cashu Group
Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), an innovation-driven Canadian cannabis processor, announces that Emma Andrews has stepped down as Chief Executive Officer, President and a director of the Company. The Board of Directors has appointed Sam Kassem, the Company's current Chief Financial Officer and a director of the Company, as Interim Chief Executive Officer
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-09-15 7:50 PM EDT | Nextleaf Solutions Ltd.
La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
AquaBounty Announces Engagement of Colliers as Exclusive Agent for its Ohio Property
Harvard, Massachusetts--(Newsfile Corp. - September 15, 2026) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty," "we," "our" or the "Company") today announced that it has engaged Colliers as its exclusive real estate agent and advisor for its Pioneer, Ohio property as part of the Company's ongoing strategic review process. The Company previously announced that it was broadening its evaluation of strategic alternatives to maximize shareholder value. The Pioneer campus posses
Agriculture, Biotechnologies, Aliments / boissons
2026-09-15 8:15 AM EDT | AquaBounty Technologies, Inc.
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
New York and Rockville, Maryland--(Newsfile Corp. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-
2026-09-15 7:46 AM EDT | OS Therapies
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Ru
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-09-15 7:00 AM EDT | Theralase Technologies Inc.
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE:
Biotechnologies, Pharmaceutique, Santé
2026-09-15 7:00 AM EDT | BioHarvest Sciences Inc.
Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on thr
2026-09-15 6:30 AM EDT | Telo Genomics Corp.
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-1
Biotechnologies, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | BioHarvest Sciences Inc.
Entheon Adopts Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that it has elected to participate in the Coordinated Blanket Order 51-933 – Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order"), issued by the Canadian Securities Administrators, and adopts semi-annual financial reporting. This news release is being filed
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-11 6:18 PM EDT | Entheon Biomedical Corp.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone. "One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scien
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-09-10 7:15 AM EDT | Resverlogix Corp.
Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting"). A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled
2026-09-09 5:05 PM EDT | Noveris Health Sciences Inc.
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at
Biotechnologies, Pharmaceutique
2026-09-09 4:30 PM EDT | InMed Pharmaceuticals
Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé
Calgary, Alberta--(Newsfile Corp. - 9 septembre 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l'approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse des 16 juillet 2026 et 19 août 2026) (le « Placement
2026-09-09 2:37 PM EDT | Marvel Biosciences Corp.
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange ("TSXV") to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the "Offering"). The deadline by which the Company must file its final closing materials with the TSXV has been extend
2026-09-09 2:32 PM EDT | Marvel Biosciences Corp.
Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy
Boston, Massachusetts--(Newsfile Corp. - September 9, 2026) - Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today highlighted the publication of research conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research in Science Advances. The paper, entitled "Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dy
2026-09-09 2:27 PM EDT | Tevard Biosciences